Anti-cytokine antibodies as carrier proteins. Prolongation of in vivo effects of exogenous cytokines by injection of cytokine-anti-cytokine antibody complexes - PubMed (original) (raw)
. 1993 Aug 1;151(3):1235-44.
Affiliations
- PMID: 8393043
Anti-cytokine antibodies as carrier proteins. Prolongation of in vivo effects of exogenous cytokines by injection of cytokine-anti-cytokine antibody complexes
F D Finkelman et al. J Immunol. 1993.
Abstract
Anti-cytokine antibodies that block interactions between cytokines and cytokine receptors have been used to inhibit endogenous cytokine function. However, injection of mice with mixtures of IL-4 and either of two neutralizing anti-IL-4 mAb, at a cytokine/anti-cytokine mAb molar ratio of approximately 2:1, enhances and prolongs in vivo IL-4 activity, as measured by induction of increased spleen cell Ia expression. Although splenocyte Ia expression returns to baseline two days after mice are injected with free IL-4, soluble IL-4-anti-IL-4 mAb complexes still induce several-fold increases in Ia expression 3 days after injection. Complexes that contain as little as 400 ng of IL-4 have considerable in vivo stimulatory activity, and a maximal effect on splenocyte Ia expression is induced by injection of 2 micrograms of complexed IL-4. The stimulatory effect of IL-4-containing complexes on splenocyte Ia expression can be blocked by increasing the ratio of anti-IL-4 mAb to IL-4, by injection of anti-IL-4R mAb, and by in vivo aggregation of the complexes. Complexes of IL-4 with a non-neutralizing anti-IL-4 mAb do not have increased IL-4 agonist activity in vivo. These observations are most consistent with the possibility that neutralizing anti-IL-4 mAb act as carrier proteins that increase the in vivo half-life of IL-4 by preventing its excretion, and possibly, by preventing modification of its active site. The enhanced agonist effect of IL-4-anti-IL-4 mAb complexes is not unique; complexes of IL-3 with a neutralizing anti-IL-3 mAb have a greatly increased ability, compared with free IL-3, to stimulate mucosal mastocytosis, and complexes of IL-7 with a neutralizing anti-IL-7 mAb have a greatly increased ability, compared with free IL-7 or IL-7 complexed with a non-neutralizing anti-IL-7 mAb, to stimulate an increase in pre-B cell number. These observations suggest that complexes of cytokines and neutralizing anti-cytokine mAb may provide a generally useful way to increase the magnitude and duration of cytokine effects in vivo.
Similar articles
- Production of BSF-1 during an in vivo, T-dependent immune response.
Finkelman FD, Ohara J, Goroff DK, Smith J, Villacreses N, Mond JJ, Paul WE. Finkelman FD, et al. J Immunol. 1986 Nov 1;137(9):2878-85. J Immunol. 1986. PMID: 3489779 - Recombinant soluble murine IL-4 receptor can inhibit or enhance IgE responses in vivo.
Sato TA, Widmer MB, Finkelman FD, Madani H, Jacobs CA, Grabstein KH, Maliszewski CR. Sato TA, et al. J Immunol. 1993 Apr 1;150(7):2717-23. J Immunol. 1993. PMID: 8454851 - In vivo biological effects of recombinant soluble interleukin-4 receptor.
Maliszewski CR, Sato TA, Davison B, Jacobs CA, Finkelman FD, Fanslow WC. Maliszewski CR, et al. Proc Soc Exp Biol Med. 1994 Jul;206(3):233-7. doi: 10.3181/00379727-206-43750. Proc Soc Exp Biol Med. 1994. PMID: 8016157 Review. - Cytokine/Antibody complexes: an emerging class of immunostimulants.
Mostböck S. Mostböck S. Curr Pharm Des. 2009;15(7):809-25. doi: 10.2174/138161209787582174. Curr Pharm Des. 2009. PMID: 19275644 Review.
Cited by
- Harnessing IL-2 for immunotherapy against cancer and chronic infection: a historical perspective and emerging trends.
Im SJ, Lee K, Ha SJ. Im SJ, et al. Exp Mol Med. 2024 Sep;56(9):1900-1908. doi: 10.1038/s12276-024-01301-3. Epub 2024 Sep 2. Exp Mol Med. 2024. PMID: 39218982 Free PMC article. Review. - Cytokine/Antibody Fusion Protein Design and Evaluation.
Fabilane CS, Stephenson AC, Leonard EK, VanDyke D, Spangler JB. Fabilane CS, et al. Curr Protoc. 2024 May;4(5):e1061. doi: 10.1002/cpz1.1061. Curr Protoc. 2024. PMID: 38775006 - Mast cell-derived interleukin-4 mediates activation of dendritic cell during toll-like receptor 2-mediated inflammation.
Friedel J, Pierre S, Kolbinger A, Schäufele TJ, Aliraj B, Weigert A, Scholich K. Friedel J, et al. Front Immunol. 2024 Apr 30;15:1353922. doi: 10.3389/fimmu.2024.1353922. eCollection 2024. Front Immunol. 2024. PMID: 38745645 Free PMC article. - Interferons and tuft cell numbers are bottlenecks for persistent murine norovirus infection.
Aggarwal S, Walker FC, Weagley JS, McCune BT, Wu X, Schriefer LA, Makimaa H, Lawrence D, Sridhar P, Baldridge MT. Aggarwal S, et al. PLoS Pathog. 2024 May 3;20(5):e1011961. doi: 10.1371/journal.ppat.1011961. eCollection 2024 May. PLoS Pathog. 2024. PMID: 38701091 Free PMC article. - Interleukin-4 downregulates transcription factor BCL6 to promote memory B cell selection in germinal centers.
Shehata L, Thouvenel CD, Hondowicz BD, Pew LA, Pritchard GH, Rawlings DJ, Choi J, Pepper M. Shehata L, et al. Immunity. 2024 Apr 9;57(4):843-858.e5. doi: 10.1016/j.immuni.2024.02.018. Epub 2024 Mar 20. Immunity. 2024. PMID: 38513666
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Research Materials
Miscellaneous